SeekingAlpha · Jan 13, 2026
Terns Pharmaceuticals, Inc. (TERN) Presents at 44th Annual J.P. Morgan Healthcare Conference - Slideshow
2026-01-13. The following slide deck was published by Terns Pharmaceuticals, Inc.
TE
NASDAQ · TERN
Terns Pharmaceuticals, Inc.
Healthcare · Biotechnology
$52.95
Down-$0.02 (-0.03%)
Updated Aug 16, 2026, 4:58 AM
SID Score
6.2/10
Composite research score
Smart Money
58/100
Neutral
- Market cap
- 4.24B
- P/E ratio
- -47.02
- Dividend yield
- 0.00%
- 52-week range
- $2.66 – $53.19
- Volume
- 6.35M
- Avg. volume
- 3.23M
Price performance
TERN price history
1M range · 0 trading sessions · Daily adjusted prices
TERN does not have enough price history for the selected period.
Data unavailable
Market data is busy. Please try again shortly.
Latest TERN news
The latest Smart Investors Daily articles mentioning TERN.
Stock researchCompany · Overview
TERN research
Overview
Company profile and research snapshot.
Company profile
Terns Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company is developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, NASH, and other chronic liver diseases. Its product candidates include TERN-701, TERN-601, TERN-501 and TERN-800.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $55.38
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Apr 27, 2026 | Oppenheimer | Perform | — |
| Apr 14, 2026 | JP Morgan | Overweight | — |
| Mar 31, 2026 | Truist Securities | Hold | — |
| Mar 30, 2026 | Barclays | Equal-Weight | — |
| Mar 26, 2026 | Citizens | Market Perform | — |
News briefing
No generated briefing is available yet.
SeekingAlpha · Jan 12, 2026
Terns Pharmaceuticals, Inc. (TERN) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Terns Pharmaceuticals, Inc. (TERN) 44th Annual J.P.
GlobeNewswire Inc. · Dec 10, 2025
Terns Announces Pricing of Upsized $650 Million Public Offering
Terns Pharmaceuticals plans to raise $650 million through a public offering of 16,250,000 shares at $40.00 per share, with proceeds intended to fund research, clinical trials, and development of product candidates like TERN-701.
seekingalpha.com · Dec 9, 2025
Terns Pharmaceuticals: CML Data Blows Wall Street Away - Again
Terns Pharmaceuticals, Inc. stock has surged 770% YTD, driven by strong TERN-701 data in chronic myeloid leukemia, or CML, the latest outstanding data set shared yesterday. TERN-701 demonstrated superior major molecular response rates versus Novartis' Scemblix, with robust safety and efficacy in heavily pre-treated CML patients. Management is prioritizing TERN-701, raising $400M for pivotal studies, with Phase 3 initiation and regulatory milestones as key upcoming catalysts.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
